GDMC Co-Founder and CEO Michael Koeris
Genetic Design and Manufacturing Corporation (GDMC), a design and manufacturing organisation focusing on next-generation advanced genetic therapies, has secured US$21 million in Series A funding.
Asian private equity firm Celadon Partners led the round, which also saw participation from WI Harper Group, SEEDS Capital, and NSG Ventures.
The funds will be used to accelerate novel technology and process efficiency improvements to drive greater manufacturing cost reductions for partners who aim to advance medicines through clinical trials and towards commercialisation.
Also Read: How NSG BioLabs aims to nurture biotech innovation in Singapore and beyond
CEO and Co-Founder Michael Koeris said: “With our recent funding, we aspire to cultivate stronger collaborations with more partners in the US and APAC region, working hand in hand to improve the state of healthcare and treatment for patients.”
Established in 2021 by Koeris, GDMC focuses on manufacturing advanced therapy modalities, including customised mRNA, plasmid DNA, AAV and Lentiviral Vectors. It has developed a Partnership for Drug Manufacturing Organisation model, offering support to companies, including startups, from drug design to being the one-stop shop for innovators from design and manufacturing to quality assurance and regulatory support for eventual market entry.
It has initiated construction on a 155,000 sq ft pre-clinical, clinical, and commercial facility supporting Cell, Gene, and Nucleic Acid Therapies (CGNT). It can help generate purpose-developed technologies to accelerate next-generation medicine design tools while leveraging Machine Learning to generate novel toolkits to overcome current challenges in manufacturing.
Also Read: Biotech is set to push new frontiers in precision oncology therapeutics
GDMC’s partnership approach is centred on improving genetic medicine design and development through synthetic biology and focusing on three market-relevant pillars: success-based partnerships with sponsors, technical innovation, and significantly lower cost of goods.
The team has already signed its first clients and is taking reservations for the clinical and commercial facilities expected to open in a staggered format from 2024 to 2027.
—
X marks Echelon. Join us at Singapore EXPO on May 15-16 for the 10th edition of Asia’s leading tech and startup conference. Enjoy 2 days of building connections with potential investors, partners, and customers, exploring innovation, and sharing insights with 8,000+ key decision-makers of Asia’s tech ecosystem. Get your tickets here.
Want more from your Echelon experience? Be an Echelon X sponsor or exhibitor. Send enquiry here.
The post GDMC nets US$21M in Series A for its next-gen advanced genetic therapies appeared first on e27.